The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa

Pathogens and Disease

Volumn 70, Issue 3, 2014, Pages 307-320

  Oglesby Sherrouse, Amanda G ^a,b   Djapgne, Louise ^a   Nguyen, Angela T ^a   Vasil, Adriana I ^c   Vasil, Michael L ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic resistance; Biofilms; Iron; Pseudomonas aeruginosa; Tigecyclin; Tobramycin

Indexed keywords

AZITHROMYCIN; CEFTAZIDIME; CIPROFLOXACIN; HEME; IMIPENEM; IRON; MEROPENEM; PIPERACILLIN; PYOVERDINE; SIDEROPHORE; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT; CATION TRANSPORT PROTEIN; IRON CHELATING AGENT; MINOCYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL VIRULENCE; BIOFILM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG TARGETING; IRON DEPLETION; IRON METABOLISM; IRON TRANSPORT; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; MUCOIDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; ANAEROBIC GROWTH; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTION;

ANAEROBIOSIS; ANTI-BACTERIAL AGENTS; BIOFILMS; CATION TRANSPORT PROTEINS; DRUG RESISTANCE, BACTERIAL; HEME; IRON; IRON CHELATING AGENTS; MINOCYCLINE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SIDEROPHORES; TOBRAMYCIN;

EID: 84920276837     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12132     Document Type: Article

References (74)

1. Allahverdiyev AM, Kon KV, Abamor ES, Bagirova M & Rafailovich M (2011) Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. Expert Rev Anti-Infect Ther 9: 1035-1052.
2. Banin E, Vasil ML & Greenberg EP (2005) Iron and Pseudomonas aeruginosa biofilm formation. P Natl Acad Sci USA 102: 11076- 11081.
3. Barker AP, Vasil AI, Filloux A, Ball G, Wilderman PJ & Vasil ML (2004) A novel extracellular phospholipase C of Pseudomonas aeruginosa is required for phospholipid chemotaxis. Mol Microbiol 53: 1089-1098.
4. Barton HA, Johnson Z, Cox CD, Vasil AI & Vasil ML (1996) Ferric uptake regulator mutants of Pseudomonas aeruginosa with distinct alterations in the iron-dependent repression of exotoxin A and siderophores in aerobic and microaerobic environments. Mol Microbiol 21: 1001-1017.
5. Beare PA, For RJ, Martin LW & Lamont IL (2003) Siderophore-mediated cell signaling in Pseudomonas aeruginosa: divergent pathways regulate virulence factor production and siderophore receptor synthesis. Mol Microbiol 47: 195-207.
6. Bendig JW, Kyle PW, Giangrande PL, Samson DM & Azadian BS (1987) Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin. J R Soc Med 80: 316-317.
7. Berlutti F, Morea C, Battistoni A, Sarli S, Cipriani P, Superti F, Ammendolia MG & Valenti P (2005) Iron availability influences aggregation, biofilm, adhesion and invasion of Pseudomonas aeruginosa and Burkholderia cenocepacia. Int J Immunopathol Pharmacol 18: 661-670.
8. Boucher JC, Yu H, Mudd MH & Deretic V (1997) Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 65: 3838- 3846.
9. Brock JH, Liceaga J & Kontoghiorghes GJ (1988) The effect of synthetic iron chelators on bacterial growth in human serum. FEMS Microbiol Immunol 1: 55-60.
10. Ceri H, Olson ME, Stremick C, Read RR, Morck D & Buret A (1999) The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37: 1771-1776.
11. Cohen AR (2006) New advances in iron chelation therapy. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program 42-47.
12. Cornelis P, Anjaiah V, Koedam N, Delfosse P, Jacques P, Thonart P & Neirinckx L (1992) Stability, frequency and multiplicity of transposon insertions in the pyoverdine region in the chromosomes of different fluorescent pseudomonads. J Gen Microbiol 138: 1337-1343.
13. Cox CD (1982) Effect of pyochelin on the virulence of Pseudomonas aeruginosa. Infect Immun 36: 17-23.
14. Cunliffe HE, Merriman TR & Lamont IL (1995) Cloning and characterization of pvdS, a gene required for pyoverdine synthesis in Pseudomonas aeruginosa: PvdS is probably an alternative sigma factor. J Bacteriol 177: 2744-2750.
15. De Vos D, De Chial M, Cochez C, Jansen S, Tummler B, Meyer JM & Cornelis P (2001) Study of pyoverdine type and production by Pseudomonas aeruginosa isolated from cystic fibrosis patients: prevalence of type II pyoverdine isolates and accumulation of pyoverdine-negative mutations. Arch Microbiol 175: 384-388.
16. Driscoll JA, Brody SL & Kollef MH (2007) The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67: 351-368.
17. Falagas ME & Bliziotis IA (2007) Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 29: 630-636.
18. Falagas ME, Karageorgopoulos DE & Nordmann P (2011) Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol 6: 653-666.
19. FitzSimmons SC (1993) The changing epidemiology of cystic fibrosis. J Pediatr 122: 1-9.
20. Frangipani E, Visaggio D, Heeb S, Kaever V, Camara M, Visca P & Imperi F (2013) The Gac/Rsm and cyclic-di-GMP signalling networks coordinately regulate iron uptake in Pseudomonas aeruginosa. Environ Microbiol DOI: 10.1111/1462-2920.12164.
21. Fyfe JA & Govan JR (1980) Alginate synthesis in mucoid Pseudomonas aeruginosa: a chromosomal locus involved in control. J Gen Microbiol 119: 443-450.
22. Ghysels B, Dieu BT, Beatson SA, Pirnay JP, Ochsner UA, Vasil ML & Cornelis P (2004) FpvB, an alternative type I ferripyoverdine receptor of Pseudomonas aeruginosa. Microbiology 150: 1671- 1680.
23. Gifford AH, Miller SD, Jackson BP, Hampton TH, O'Toole GA, Stanton BA & Parker HW (2011) Iron and CF-related anemia: expanding clinical and biochemical relationships. Pediatr Pulmonol 46: 160-165.
24. Gill JF, Deretic V & Chakrabarty AM (1987) Alginate production by the mucoid Pseudomonas aeruginosa associated with cystic fibrosis. Microbiol Sci 4: 296-299.
25. Gray RD, Duncan A, Noble D, Imrie M, O'Reilly DS, Innes JA, Porteous DJ, Greening AP & Boyd AC (2010) Sputum trace metals are biomarkers of inflammatory and suppurative lung disease. Chest 137: 635-641.
26. Hatch RA & Schiller NL (1998) Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother 42: 974-977.
27. Heinz U, Hegetschweiler K, Acklin P, Faller B, Lattmann R & Schnebli HP (1999) 4-[3,5-Bis(2-hydroxyphenyl)-1,2, 4-triazol- 1-yl]-benzoic acid: a novel efficient and selective iron (iii) complexing agent. Angew Chem Int Ed Engl 38: 2568- 2570.
28. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA & Miller SI (2005) Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436: 1171-1175.
29. Hoiby N, Bjarnsholt T, Givskov M, Molin S & Ciofu O (2010) Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35: 322-332.
30. Holloway BW (1955) Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol 13(3): 572-581.
31. Hunter RC, Asfour F, Dingemans J, Osuna BL, Samad T, Malfroot A, Cornelis P & Newman DK (2013) Ferrous iron is a significant component of bioavailable iron in cystic fibrosis airways. MBio 4(4): e00557-13. doi: 10.1128/mBio.00557-13.
32. Lamont IL, Beare PA, Ochsner U, Vasil AI & Vasil ML (2002) Siderophore-mediated signaling regulates virulence factor production in Pseudomonas aeruginosa. P Natl Acad Sci USA 99: 7072-7077.
33. Lyczak JB, Cannon CL & Pier GB (2000) Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2: 1051-1060.
34. Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL & Oliver A (2005) Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 49: 3382-3386.
35. Manning T, Kean G, Thomas J, Thomas K, Corbitt M, Gosnell D, Ware R, Fulp S, Jarrard J & Phillips D (2009) Iron chelators in medicinal applications-chemical equilibrium considerations in pharmaceutical activity. Curr Med Chem 16: 2416-2429.
36. Marlovits TC, Haase W, Herrmann C, Aller SG & Unger VM (2002) The membrane protein FeoB contains an intramolecular G protein essential for Fe(II) uptake in bacteria. P Natl Acad Sci USA 99: 16243-16248.
37. Marshall B, Stintzi A, Gilmour C, Meyer JM & Poole K (2009) Citrate-mediated iron uptake in Pseudomonas aeruginosa: involvement of the citrate-inducible FecA receptor and the FeoB ferrous iron transporter. Microbiology 155: 305-315.
38. Mateos F, Brock JH & Perez-Arellano JL (1998) Iron metabolism in the lower respiratory tract. Thorax 53: 594-600.
39. Meyer J, Neely A, Stintzi A, Georges C & Holder I (1996) Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect Immun 64: 518-523.
40. Meyer JM, Stintzi A, De Vos D, Cornelis P, Tappe R, Taraz K & Budzikiewicz H (1997) Use of siderophores to type pseudomonads: the three Pseudomonas aeruginosa pyoverdine systems. Microbiology 143(Pt 1): 35-43.
41. Mihu MR & Martinez LR (2011) Novel therapies for treatment of multi-drug resistant Acinetobacter baumannii skin infections. Virulence 2: 97-102.
42. Moradpour Z & Ghasemian A (2011) Modified phages: novel antimicrobial agents to combat infectious diseases. Biotechnol Adv 29: 732-738.
43. Moreau-Marquis S, Bomberger JM, Anderson GG, Swiatecka- Urban A, Ye S, O'Toole GA & Stanton BA (2008) The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 295: L25-L37.
44. Moreau-Marquis S, O'Toole GA & Stanton BA (2009) Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol 41: 305-313.
45. Navon-Venezia S, Leavitt A & Carmeli Y (2007) High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59: 772-774.
46. Ochsner UA, Johnson Z, Lamont IL, Cunliffe HE & Vasil ML (1996) Exotoxin A production in Pseudomonas aeruginosa requires the iron-regulated pvdS gene encoding an alternative sigma factor. Mol Microbiol 21: 1019-1028.
47. Ochsner UA, Johnson Z & Vasil ML (2000) Genetics and regulation of two distinct haem-uptake systems, phu and has, in Pseudomonas aeruginosa. Microbiology 146(Pt 1): 185-198.
48. Ochsner UA, Wilderman PJ, Vasil AI & Vasil ML (2002) GeneChip expression analysis of the iron starvation response in Pseudomonas aeruginosa: identification of novel pyoverdine biosynthesis genes. Mol Microbiol 45: 1277-1287.
49. Oglesby AG, Farrow JM, Lee JH, Tomaras AP, Greenberg EP, Pesci EC & Vasil ML (2008) The influence of iron on Pseudomonas aeruginosa physiology: a regulatory link between iron and quorum sensing. J Biol Chem 283: 15558-15567.
50. Parad RB, Gerard CJ, Zurakowski D, Nichols DP & Pier GB (1999) Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 67: 4744-4750.
51. Patriquin GM, Banin E, Gilmour C, Tuchman R, Greenberg EP & Poole K (2008) Influence of quorum sensing and iron on twitching motility and biofilm formation in Pseudomonas aeruginosa. J Bacteriol 190: 662-671.
52. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE & Testa RT (1999) In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43: 738-744.
53. Pruitt JBA, McManus AT, Kim SH & Goodwin CW (1998) Burn wound infections: current status. World J Surg 22: 135-145.
54. Reid DW, Withers NJ, Francis L, Wilson JW & Kotsimbos TC (2002) Iron deficiency in cystic fibrosis: relationship to lung disease severity and chronic Pseudomonas aeruginosa infection. Chest 121: 48-54.
55. Reid DW, Lam QT, Schneider H & Walters EH (2004) Airway iron and iron-regulatory cytokines in cystic fibrosis. Eur Respir J 24: 286-291.
56. Rogers HJ (1973) Iron-binding catechols and virulence in Escherichia coli. Infect Immun 7: 438-444.
57. Ryder C, Byrd M & Wozniak DJ (2007) Role of polysaccharides in Pseudomonas aeruginosa biofilm development. Curr Opin Microbiol 10: 644-648.
58. Schwyn B & Neilands JB (1987) Universal chemical assay for the detection and determination of siderophores. Anal Biochem 160: 47-56.
59. Singh PK (2004) Iron sequestration by human lactoferrin stimulates P. aeruginosa surface motility and blocks biofilm formation. Biometals 17: 267-270.
60. Singh PK, Parsek MR, Greenberg EP & Welsh MJ (2002) A component of innate immunity prevents bacterial biofilm development. Nature 417: 552-555.
61. Stites SW, Walters B, O'Brien-Ladner AR, Bailey K & Wesselius LJ (1998) Increased iron and ferritin content of sputum from patients with cystic fibrosis or chronic bronchitis. Chest 114: 814-819.
62. Stites SW, Plautz MW, Bailey K, O'Brien-Ladner AR & Wesselius LJ (1999) Increased concentrations of iron and isoferritins in the lower respiratory tract of patients with stable cystic fibrosis. Am J Respir Crit Care Med 160: 796-801.
63. Sum PE & Petersen P (1999) Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 9: 1459-1462.
64. Takase H, Nitanai H, Hoshino K & Otani T (2000a) Impact of siderophore production on Pseudomonas aeruginosa infections in immunosuppressed mice. Infect Immun 68: 1834-1839.
65. Takase H, Nitanai H, Hoshino K & Otani T (2000b) Requirement of the Pseudomonas aeruginosa tonB gene for high-affinity iron acquisition and infection. Infect Immun 68: 4498-4504.
66. Visca P, Imperi F & Lamont IL (2007) Pyoverdine siderophores: from biogenesis to biosignificance. Trends Microbiol 15: 22-30.
67. Waine DJ, Honeybourne D, Smith EG, Whitehouse JL & Dowson CG (2008) Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa. J Clin Microbiol 46: 3491-3493.
68. Wiener-Kronish JP & Pittet JF (2011) Therapies against virulence products of Staphylococcus aureus and Pseudomonas aeruginosa. Semin Respir Crit Care Med 32: 228-235.
69. Wilderman PJ, Vasil AI, Johnson Z, Wilson MJ, Cunliffe HE, Lamont IL & Vasil ML (2001) Characterization of an endoprotease (PrpL) encoded by a PvdS-regulated gene in Pseudomonas aeruginosa. Infect Immun 69: 5385-5394.
70. Wilderman PJ et al. (2004) Identification of tandem duplicate regulatory small RNAs in Pseudomonas aeruginosa involved in iron homeostasis. P Natl Acad Sci USA 101(26): 9792-9797.
71. Willcox MD (2007) Pseudomonas aeruginosa infection and inflammation during contact lens wear: a review. Optom Vis Sci 84: 273-278.
72. Wilson MJ & Lamont IL (2000) Characterization of an ECF sigma factor protein from Pseudomonas aeruginosa. Biochem Biophys Res Commun 273: 578-583.
73. Worlitzsch D, Tarran R, Ulrich M et al. (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109: 317-325.
74. 3+ chelates. Inorg Chem 42: 5412-5421.